Shaanxi Kanghui Pharmaceutical Co Ltd

SHSE:603139

Kina / Sjukvård / Läkemedel

Översikt

Utdelning

5 års historiska finanser

Aktiepris

18,77 CNY


Key Metrics	Latest
Total Revenue	605,3 M
Adjusted EBITDA	12,303 M
EBITDA Margin	2,0%
Net Profit Margin	-11,7%
Total Assets	2,007 B
Total Debt	696,6 M

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	12 Months	Sep-23	Sep-24

Revenue	431.42	414.07	442.76	491.51	672.96	605.28	472.23	404.55
% Growth		(0.04)	0.07	0.11	0.37			(0.14)

Adjusted EBITDA	58.58	46.21	34.64	17.18	39.02	12.30	27.94	1.21
% Margin	0.14	0.11	0.08	0.03	0.06	0.02	0.06	0.00

Adjusted EBIT	46.68	34.25	18.27	(8.17)	1.37	(34.58)	8.93	(27.02)
% Margin	0.11	0.08	0.04	(0.02)	0.00	(0.06)	0.02	(0.07)

Adjusted Net Income	46.41	34.98	24.70	(28.13)	(22.60)	(70.69)	(0.63)	(48.72)
% Margin	0.11	0.08	0.06	(0.06)	(0.03)	(0.12)	(0.00)	(0.12)

Adjusted Basic EPS	0.47	0.35	0.25	(0.28)	(0.22)	(0.71)	(0.01)	(0.48)

Stödjande beräkningar

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Original
CNY	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Sep-24	Sep-23	Sep-24
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	431	414	443	492	673	605	472	405
% Growth	NA	-4.0%	6.9%	11.0%	36.9%			-14.3%

Cost of Revenue	(228)	(221)	(242)	(303)	(489)	(430)	(333)	(275)
Gross Profit	203	193	201	188	184	175	139	130
% Revenue	47.0%	46.5%	45.4%	38.3%	27.3%	28.9%	29.4%	32.1%

Research and Development	(8)	(10)	(10)	(12)	(24)	(21)	(7)	(5)
Selling and Marketing	(123)	(116)	(138)	(138)	(122)	(140)	(87)	(105)
General and Admin	(19)	(28)	(31)	(43)	(44)	(54)	(33)	(43)
Other Inc / (Exp)	(7)	(2)	6	(70)	(33)	(36)	(0)	(3)
Total Operating Exp	(158)	(156)	(173)	(264)	(224)	(251)	(128)	(156)

Operating Income	45	36	28	(75)	(40)	(76)	11	(26)
% Revenue	10.4%	8.8%	6.3%	-15.3%	-5.9%	-12.6%	2.3%	-6.3%

Interest Expense	11	7	11	(8)	(18)	(31)	(8)	(21)
Pre-tax Income	56	44	39	(83)	(58)	(107)	3	(46)
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0
Provision for Taxes	(10)	(7)	(6)	6	7	7	(2)	(2)
Net Income to Company	46	36	33	(77)	(51)	(100)	1	(48)
% Margin	10.7%	8.8%	7.5%	-15.6%	-7.5%	-16.5%	0.2%	-11.8%

Minority Interest in Earnings	(3)	(2)	3	14	25	26	8	9
Net Income to Stockholders	43	34	36	(63)	(26)	(74)	9	(38)

Preferred Dividends	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0

Net Income to Common	43	34	36	(63)	(26)	(74)	9	(38)
% Margin	9.9%	8.2%	8.2%	-12.8%	-3.9%	-12.2%	2.0%	-9.5%

As Reported
Basic EPS (Continuing Ops)	0.43	0.34	0.37	(0.63)	(0.26)	(0.73)	0.09	(0.38)
Diluted EPS (Continuing Ops)	0.43	0.34	0.37	(0.63)	(0.26)	(0.73)	0.09	(0.38)

WA Basic Shares Out.	99.45	100.33	98.60	100.09	100.61	98.91	102.46	100.76
WA Diluted Shares Out.	99.45	100.33	98.60	100.09	100.61	98.91	102.46	100.76

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	56	44	39	(83)	(58)	(107)	3	(46)
Addback: Net Interest Expense	(11)	(7)	(11)	8	18	31	8	21
Addback: Other Non Operating Expenses, Total	1	(0)	2	1	3	3	0	(0)
Addback: Depreciation & Amortization	12	12	16	25	38	47	19	28
Addback: Restructuring Charges	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	5	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	0	(9)	55	29	27	0	(2)
Addback: Gain (Loss) On Sale Of Assets	(0)	0	0	7	(0)	0	(0)	0
Addback: Asset Writedown	0	0	0	0	17	20	(2)	1
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	0	(2)	(2)	(1)	(7)	(7)	0	0
Adjusted EBITDA	59	46	35	17	39	12	28	1
% Margin	13.6%	11.2%	7.8%	3.5%	5.8%	2.0%	5.9%	0.3%

Adjusted EBIT	47	34	18	(8)	1	(35)	9	(27)
% Margin	10.8%	8.3%	4.1%	-1.7%	0.2%	-5.7%	1.9%	-6.7%

Adjusted Net Income Reconciliation
Net Income to Company	46	36	33	(77)	(51)	(100)	1	(48)
Addback: Unusual Items	0	(2)	(11)	66	38	39	(2)	(1)
Less: Tax Benefit of Unusual Items (26%)	(0)	1	3	(17)	(10)	(10)	1	0
Adjusted Net Income	46	35	25	(28)	(23)	(71)	(1)	(49)
% Margin	10.8%	8.4%	5.6%	-5.7%	-3.4%	-11.7%	-0.1%	-12.0%

Med ensamrätt. Användarvillkor

Laddningsfel

Shaanxi Kanghui Pharmaceutical Co Ltd

SHSE:603139

Kina / Sjukvård / Läkemedel

5 års historiska finanser